🇺🇸 Catapresan TTS 2 in United States

33 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 33

Most-reported reactions

1. Cardiac Failure — 7 reports (21.21%)
2. Ejection Fraction Decreased — 5 reports (15.15%)
3. Respiratory Acidosis — 5 reports (15.15%)
4. Anaemia — 3 reports (9.09%)
5. Hypertensive Crisis — 3 reports (9.09%)
6. Bradycardia — 2 reports (6.06%)
7. Confusional State — 2 reports (6.06%)
8. Drug Ineffective — 2 reports (6.06%)
9. Dyspnoea — 2 reports (6.06%)
10. Face Oedema — 2 reports (6.06%)

Source database →

Frequently asked questions

Is Catapresan TTS 2 approved in United States?

Catapresan TTS 2 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Catapresan TTS 2 in United States?

Heart Care Foundation is the originator. The local marketing authorisation holder may differ — check the official source linked above.